Strontiumranelat in der Therapie der postmenopausalen Osteoporose bei erst- und vorbehandelten Patientinnen

J. D. Ringe

doi:10.1055/s-0037-1619937

Osteologie, Table of Contents

Osteologie 2010; 19(02): 157-164
DOI: 10.1055/s-0037-1619937

Originalund Übersichtsarbeiten

Schattauer GmbH

Strontiumranelat in der Therapie der postmenopausalen Osteoporose bei erst- und vorbehandelten Patientinnen

Ergebnisse der OLYMP-PraxisstudieStrontium ranelate in the therapy of postmenopausal osteoporosis at first and pre-treated patients: results of the OLYMP practice study

J. D. Ringe

¹Westdeutsches Osteoporose Zentrum (WOZ) und Med. Klinik 4, Klinikum Leverkusen, Akadem. Lehrkrankenhaus der Universität zu Köln

› Author Affiliations

Abstract

Zusammenfassung

Ziel: Die prospektive, nichtinterventionelle OLYMP-Studie untersucht die Wirkung von Strontiumranelat (SR) bei postmenopausaler Osteoporose (PMO) hinsichtlich Schmerzen und Lebensqualität unter Praxisbedingungen.

Design: 3383 Patienten mit PMO wurden von 1131 niedergelassenen Ärzten in Deutschland mit SR 2 g einmal täglich oral über drei Monate therapiert. Lebensqualität (QoL), Schmerzen, Komedikation, Frakturen, Knochendichte, Verträglichkeit und Compliance wurden deskriptiv an 3164 Patienten (ITT) analysiert. 39,1 % der Patienten waren mit Bisphosphonaten (BP) vorbehandelt, 26 % der Patienten waren > 75 Jahre alt.

Ergebnisse: Nach drei Monaten SR verbesserten sich die Schmerzen um 32,3 % (Patienten mit BP-Vorbehandlung: 28,3 %, Patienten ohne Vorbehandlung: 35,6 %, Patienten > 75 Jahre: 28,6 %) und die QoL um 27,5 % (Patienten mit BP-Vorbehandlung: 24,5 %, Patienten ohne Vorbehandlung: 30,2 %, Patienten > 75 Jahre: 24,4 %). SR wurde bei 93 % der Patienten als sehr gut bzw. gut bewertet und bei 93,2 % der Patienten nach drei Monaten fortgesetzt. UAWs traten bei 2,4 % der Patienten auf.

Zusammenfassung: OLYMP bestätigt unter Praxisbedingungen die gute Wirksamkeit und Verträglichkeit von SR bei PMO unabhängig von Alter und BP-Vorbehandlung mit einer raschen Schmerzreduktion und Verbesserung der QoL.

Summary

Aim: The prospective non-interventional OLYMP-study analysed the therapeutic effects of strontium ranelate (SR) in the therapy of postmenopausal osteoporosis (PMO) with respect to pain and the quality of life under routine practice.

Design: 3383 patients with PMO were treated by 1131 physicians in Germany with SR, 2 g once daily orally for 3 months. Quality of life (QoL), pain, co-medication, fractures, BMD, tolerability and compliance were descriptively documented in 3164 patients (ITT). 39.1 % of the patients were pre-treated with bisphosphonates (BP), 26 % were > 75 years old.

Results: After 3 months with SR, pain was reduced by 32.3 % (with BP pre-treated patients: −28.3 %; patients without pre-treatment: −35.6 %; patients > 75 y.: −28.6 %). QoL improved by 27.5 % (in BP pre-treated patients: +24.5 %; patients without pre-treatment: +30.2 %; patients >75 y.: +24.4 %). 93 % of the patients reported SR as good or very good, 93.2 % continued SR therapy. Adverse events occurred in 2.4 % of the patients.

Conclusion: The OLYMP-study confirmed under daily practice conditions the good efficacy and tolerability of SR in PMO patients, independent of age or pre-treatment with BP, with an early improvement in the quality of life and a reduction in pain.

Schlüsselwörter

Postmenopausale Osteoporose - Strontiumranelat - OLYMP-Studie - Bisphosphonat-Vorbehandlung

Keywords

Postmenopausal osteoporosis - strontium ranelate - OLYMP - pre-treatment with bisphosphonates

Full Text

References

Literatur
1 Atkins GJ. et al. Strontium ranelate treatment of human primary osteoblasts promotes an osteocytelike phenotype while eliciting an osteoprotegerin response. Osteoporos Int 2009; 20 (04) 653-664.
2 Cauley JA, Thompson DE, Ensrud KC. et al. Risk of mortality following clinical fractures. Osteoporos Int 2000; 11 (07) 556-561.
3 Cummings SR, Melton L. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761-1767.
4 Dachverband Osteologie e. V. (DVO). OsteoporoseLeitlinie. Prophylaxe, Diagnostik und Therapie – bei Frauen ab der Menopause, bei Männern ab dem 60. Lebensjahr. Stuttgart: Schattauer 2006.
5 DVO-Leitlinie. Osteoporose des älteren Menschen. 2003 www.dv-osteologie.org/uploads/archiv/arch iv2003/leitl_kf_alter.pdf.
6 Fachinformation. Protelos 2 g. 2009.
7 Gennari C. Analgesic effect of calcitonin in osteoporosis. Bone 2002; 30 (05) 67S-70S.
8 Häussler B, Gothe H, Göl D. et al. Epidemiology, treatment and costs of osteoporosis in Germany: the BoneEVA study. Osteoporos Int 2007; 18 (01) 77-84.
9 Kado DM, Browner WS, Palermo L. et al. Vertebral fractures and mortality in older women: the study of osteoporotic fractures. Arch Int Med 1999; 338: 355-358.
10 Kanis J, Burlet N, Cooper C. et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008; 19: 399-428.
11 Linde L, Sörensen J, Ostergaard M. et al. Health-related quality of life: validity, reliability and responsiveness of SF-36, 15D, EQ-5D[corrected]RAQoL, and HAQ in patients with rheumatoid arthritis. J Rheumatol 2008; 35 (08) 1528-1537.
12 Marquis P, Cialdella P, De la Loge C. Development and validation of a specific quality of life module in post-menopausal women with osteoporosis: the QUALIOST. Quality of Life Research 2001; 10: 555-566.
13 Marquis P, De La Loge C, Diaz-Curiel M. et al. Beneficial effects of Strontium ranelate on the quality of life in patients with vertebral Osteoporosis. Osteoporos Int. 2005 16. 54 Abstract P223.
14 Marquis P, Roux C, Diaz-Curiel M. et al. Long-term beneficial effects of strontium ranelate on the quality of life in patients with vertebral osteoporosis (SOTI study). Osteoporos Int. 2007 18. (Suppl 1): 123, P296.
15 McCarthy M, Chang C, Pickard A. et al. Visual Analog Scales for Assessing Surgical Pain. J Am Coll Surg 2005; 201 (02) 245-252.
16 Meunier PJ, Reginster JY. Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis. Osteoporos Int 2003; 14 (Suppl. 03) S66-S76.
17 Meunier PJ, Roux C, Seeman E. et al. The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women With Postmenopausal Osteoporosis. New England Journal of Medicine 2004; 350 (05) 459-468.
18 Reginster JY, Felsenberg D, Boonen S. et al. Effects of long-term strontium ranelate treatment on the risk of non.vertebral and vertebral fractures in postmenopausal osteoporosis: results of a 5-year, randomized, placebo-controlled trial. Arthritis and Rheum 2008; 58 (06) 1687-1695.
19 Reginster JY, Sawicki A, Roces AVarela. et al. Strontium ranelate 8 years efficacy on vertebral and non vertebral fractures in postmenopausal osteoporotic women. Osteoporos Int. 2008 19. Suppl 1 P311, S131.
20 Reginster JY, Seeman E, De Vernejoul MC. et al. Strontium Ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: TROPOS Study. J Clin Endocrinol Metab 2005; 90 (05) 2816-2822.
21 Ringe JD. Strontiumranelat bei postmenopausaler Osteoporose. Arzneimitteltherapie 2007; 25 (06) 216-221.
22 Ringe JD, Dorst A, Faber H, Farahmand P. Treatment of osteoporosis in men with Strontium ranelate: results of a prospective controlled trial in 152 patients. Osteoporos Int. 2008 19. Suppl. 1: 13, OC24.
23 Seeman E, Vellas B, Benhamou C. et al. Strontium ranelate reduces risk of vertebral and non-vertebral fractures in women aged eighty years and older. J Bone Miner Res 2006; 21 (07) 1113-1120.
24 Seeman E, Vellas B, Benhamou C. et al. Sustained 5-year vertebral and non-vertebral fracture risk reduction with Strontiumranelate in elderly women with Osteoporosis. Osteoporos Int. 2006 18. (02): Abstract OC 39.
25 Seeman E, Vellas B, Roux C. et al. First Demonstration Of The Efficacy of An Anti-Osteoporotic Treatment In Very Elderly Osteoporotic Women. JBMR 2004; 19 (01) S57.